Long-Term Efficacy of Pegylated Interferon Alpha-2b in Behcet's Uveitis: A Small Case Series
Long-Term Efficacy of Pegylated Interferon Alpha-2b in Behcet's Uveitis: A Small Case Series
复制标题
DOI：
10.1080/09273948.2017.1332768
复制
发表时间：
2019-01-02
影响因子：
3.3
通讯作者：
Direskeneli, Haner
中科院分区：
文献类型：
--
作者：
Celiker, Hande;Kazokoglu, Haluk;Direskeneli, Haner
目的：评价聚乙二醇干扰素α-2b（peg-IFN-α-2b）治疗与白塞病相关的严重葡萄膜炎的长期疗效和安全性。方法：以0.5 - 1.5 μ g/kg/周的初始剂量给予PEG-IFN-α-2b。如果观察到任何并发症，则逐渐减少剂量。对患者的眼部检查、全身检查结果和治疗依从性进行评价。结果：所有患者（n = 4）的眼部炎症均得到控制。由于病例数量较少，给药后视力平均增加0.425 +/-0.125 logMAR，无统计学显著性（Wilcoxon检验，p = 0.066）。随着剂量的降低，任何实验室异常的副作用均恢复至基线水平。由于注射频率降低，患者满意度增加。结论：本系列研究强调了PEG-IFN-α-2b在白塞葡萄膜炎中的应用。聚乙二醇干扰素-α-2b对于治疗严重葡萄膜炎具有潜在的长期治疗效果。减少注射次数的疗效改善了Behcet患者的生活质量。
Purpose: To assess the long-term efficacy and safety of pegylated interferon alpha-2b (peg-IFN-alpha-2b) for severe uveitis associated with Behcet's disease. Methods: Peg-IFN-alpha-2b was administrated at an initial dosage of 0,5-1,5 mu g/kg/week. If any complications were observed, the dosage was tapered. Ocular examinations, systemic findings, and treatment compliance of the patients were evaluated. Results: Control of ocular inflammation was achieved in all patients (n = 4). The average increase in visual acuity after drug administration of 0,425 +/- 0,125 logMAR was not statistically significant (Wilcoxon Test, p = 0,066) due to small number of cases. Any side-effects with laboratory abnormalities returned to baseline levels with reduction of the doses. Due to less frequent injections, increased satisfaction of the patients was noted. Conclusions: This series highlights the peg-IFN-alpha-2b administration in Behcet's uveitis. Peg-IFN-alpha-2b has a potential long-term therapeutic effect for the treatment of severe uveitis. Efficacy with a reduced number of injections improved the quality of Behcet patients' lives.